Compare OLPX & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLPX | TNDM |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2021 | 2013 |
| Metric | OLPX | TNDM |
|---|---|---|
| Price | $2.03 | $16.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 19 |
| Target Price | $1.89 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 3.9M | 2.9M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $422,960,000.00 | ★ $1,014,736,000.00 |
| Revenue This Year | $2.95 | $8.11 |
| Revenue Next Year | $3.39 | $11.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 0.07 | ★ 7.93 |
| 52 Week Low | $0.99 | $10.00 |
| 52 Week High | $2.06 | $29.65 |
| Indicator | OLPX | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 54.22 | 46.74 |
| Support Level | $2.02 | $12.32 |
| Resistance Level | $2.04 | $21.42 |
| Average True Range (ATR) | 0.01 | 1.37 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 16.67 | 37.02 |
Olaplex Holdings Inc is a science-enabled, technology-driven beauty company. It offers science-backed solutions that improve hair health. It identifies the majority of consumers' relevant haircare concerns in collaboration with the community of professional hairstylists and consumers and strives to address them through its proprietary technology and innovation capabilities. It offers products through an omnichannel platform that serves professional, specialty retail, and DTC channels. The company derives its revenue through the sale of its hair care products. The company generates the majority of revenue from Professional sales channels followed by Specialty Retail and then DTC. Geographically the company generates the majority of its revenue from the International market.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.